Why the study?
Pulmonary embolism and cerebrovascular disease are major global causes of mortality that may share common risk factors, but long-term concurrent mortality trends were uncharacterized.
Population
59,075 U.S. decedents aged over 25 years with both PE and cerebrovascular diseases recorded on death certificates
Comparison
Trends across sex, age, race, region, and urbanization level from 1999 to 2023
Design
National death certificate-based observational trend study using Joinpoint regression
Key result
Age-adjusted mortality rate for combined pulmonary embolism and cerebrovascular disease in U.S. adults increased by 55% from 1.00 to 1.55 per 100,000 with an average annual percent increase of 1.93% over 1999–2023.
Authors
Loading...
Warrants heightened clinical vigilance for concurrent pulmonary embolism and cerebrovascular disease; extends evidence of a growing burden accelerated during COVID-19.
Observational (n=59,075)
Yes
Effect estimate: AAPC 1.93% (95% CI 0.91 to 2.97%) increase in AAMR from 1999 to 2023 (95% CI 0.91 to 2.97%)
Absolute Event Rate: 1.55% vs 1%
p-value: p=<0.05
Age-adjusted mortality for concurrent pulmonary embolism and cerebrovascular disease in the U.S. increased significantly from 1999 to 2023, highlighting a growing public health burden that accelerated during the COVID-19 pandemic.
Lv et al. (2026) conducted an observational in U.S. adults aged over 25 years with death certificates recording concurrent pulmonary embolism and cerebrovascular diseases (n=59,075). Age-adjusted mortality rate for combined pulmonary embolism and cerebrovascular disease in U.S. adults increased by 55% from 1.00 to 1.55 per 100,000 with an average annual percent increase of 1.93% over 1999–2023.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: